Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Asahi Kasei to Buy Calliditas, Bag 1st Therapy for IgA Nephropathy
May 29, 2024
-
BUSINESS AbbVie Japan Eyes Sales of 200 Billion Yen in 5 Years, Rinvoq and Skyrizi as Drivers
May 29, 2024
-
BUSINESS Fuji Pharma Charts Its Future as Japan’s Leading Biosimilar Player, Stelara Follow-On as Pace Setter
May 28, 2024
-
BUSINESS Nippon Shinyaku’s DMD Drug Misses Mark in Confirmatory Study
May 28, 2024
-
BUSINESS MSD Chief Urges Further Reform around Spillovers; Japan Sales Up 11% in 2023
May 27, 2024
-
REGULATORY LDP’s Social Security Commission Urges Govt to Revisit Off-Year Drug Price Revisions
May 24, 2024
-
ORGANIZATION JPMA, PhRMA, EFPIA to Jointly Survey Views on 2024 Drug Pricing Reform
May 24, 2024
-
BUSINESS Big 4 Wholesalers Log 11.7% Growth in Operating Profit, 3 Hit 1%-Plus Margins
May 24, 2024
-
REGULATORY Japan Govt to Launch Public-Private Forum to Attract Investments
May 23, 2024
-
BUSINESS AstraZeneca’s Beyfortus, Pfizer’s Elrexfio and More Now Available in Japan
May 23, 2024
-
BUSINESS Servier Trains Sight on 50% Oncology Sales Ratio by 2030, Set to Upsize Japan Biz
May 22, 2024
-
REGULATORY Off-Year Price Revisions Should Either Be Abolished or Revisited: LDP Lawmakers
May 21, 2024
-
REGULATORY Bridion Sees Rare May Generic Entry for New Dosage Form in Japan
May 21, 2024
-
REGULATORY Japan’s 1st Stelara Biosimilar Gets Listing, New Kit Products Too
May 21, 2024
-
BUSINESS Towa, Sawai See Continued Growth in Japan in FY2024 amid New WPP Strategies
May 20, 2024
-
BUSINESS Amylyx Pulls Out from Japan after ALS Trial Flop
May 20, 2024
-
REGULATORY Government’s Pharma Innovation Panel to Propose Comprehensive Upgrades in Industry Policies
May 17, 2024
-
REGULATORY First Innovation Premium in 6 Years Axed for Sargmalin, “Zero” Rule Hits Yet Again
May 16, 2024
-
REGULATORY Chuikyo OKs Listing of 18 Meds, All Get Price Premiums; Biggest Peak Sales for Beyfortus
May 16, 2024
-
REGULATORY Alexion Takes Hit from 1st Market Expansion Re-Pricing of Ultomiris, Soliris
May 16, 2024
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…